In conclusion, we developed a GA/ICG co-loaded nanocarrier with tumor targeting capabilities designed to activate systemic antitumor immune response by inducing pyroptosis of CC cells, boosting the efficacy of PD-1 blockade, and arresting tumor growth. This evidence concerns the gene PDCD1 and neoplasm.